MDC Stock Overview
Medlab Clinical Limited, a biotechnology company, researches, develops, and commercializes pharmaceutical and nutraceutical products in Australia.
+ 1 more risk
Medlab Clinical Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.078|
|52 Week High||AU$0.20|
|52 Week Low||AU$0.077|
|1 Month Change||-25.71%|
|3 Month Change||-35.00%|
|1 Year Change||-55.43%|
|3 Year Change||-80.25%|
|5 Year Change||-90.13%|
|Change since IPO||-61.00%|
Recent News & Updates
Shareholders May Be More Conservative With Medlab Clinical Limited's (ASX:MDC) CEO Compensation For Now
Shareholders of Medlab Clinical Limited ( ASX:MDC ) will have been dismayed by the negative share price return over the...
Is Medlab Clinical (ASX:MDC) In A Good Position To Invest In Growth?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
|MDC||AU Biotechs||AU Market|
Return vs Industry: MDC underperformed the Australian Biotechs industry which returned -9% over the past year.
Return vs Market: MDC underperformed the Australian Market which returned 0.5% over the past year.
|MDC Average Weekly Movement||10.6%|
|Biotechs Industry Average Movement||9.9%|
|Market Average Movement||9.3%|
|10% most volatile stocks in AU Market||16.3%|
|10% least volatile stocks in AU Market||4.2%|
Stable Share Price: MDC is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: MDC's weekly volatility (11%) has been stable over the past year.
About the Company
Medlab Clinical Limited, a biotechnology company, researches, develops, and commercializes pharmaceutical and nutraceutical products in Australia. Its lead drug candidate includes NanaBis, an oro–buccal administered equimolar tetrahydrocannabinol (THC) and cannabidiol (CBD) formulation as monotherapy, which is in phase 3 multi-centre, quadruple-blind, randomized- withdrawal active, and placebo-controlled clinical study for the management of opioid-requiring–bone–pain due to metastatic cancer. The company also develops NanoCelle, a patented sub-micron drug delivery platform that enhances drug solubility issues and enables faster absorption and metabolism of active ingredients.
Medlab Clinical Fundamentals Summary
|MDC fundamental statistics|
Is MDC overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MDC income statement (TTM)|
|Cost of Revenue||AU$2.78m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.035|
|Net Profit Margin||-268.08%|
How did MDC perform over the long term?See historical performance and comparison
How is Medlab Clinical forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MDC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MDC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MDC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MDC's revenue (26.1% per year) is forecast to grow faster than the Australian market (4.8% per year).
High Growth Revenue: MDC's revenue (26.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MDC's Return on Equity is forecast to be high in 3 years time
How has Medlab Clinical performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MDC is currently unprofitable.
Growing Profit Margin: MDC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MDC is unprofitable, and losses have increased over the past 5 years at a rate of 27.3% per year.
Accelerating Growth: Unable to compare MDC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MDC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.7%).
Return on Equity
High ROE: MDC has a negative Return on Equity (-101.43%), as it is currently unprofitable.
How is Medlab Clinical's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: MDC's short term assets (A$13.7M) exceed its short term liabilities (A$3.3M).
Long Term Liabilities: MDC's short term assets (A$13.7M) exceed its long term liabilities (A$965.6K).
Debt to Equity History and Analysis
Debt Level: MDC is debt free.
Reducing Debt: MDC has no debt compared to 5 years ago when its debt to equity ratio was 6.6%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MDC has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: MDC has less than a year of cash runway if free cash flow continues to reduce at historical rates of 20.8% each year
What is Medlab Clinical current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MDC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MDC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MDC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MDC's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as MDC has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Dr. Sean Michael Hall serves as the Chief Executive Officer at Medlab Clinical Limited and served as its Managing Director. He served as a Managing Director of Medlab Clinical Limited until November 2020....
CEO Compensation Analysis
Compensation vs Market: Sean's total compensation ($USD481.07K) is above average for companies of similar size in the Australian market ($USD287.06K).
Compensation vs Earnings: Sean's compensation has increased whilst the company is unprofitable.
Experienced Board: MDC's board of directors are considered experienced (7.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: MDC insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Medlab Clinical Limited's employee growth, exchange listings and data sources
- Name: Medlab Clinical Limited
- Ticker: MDC
- Exchange: ASX
- Founded: 2012
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: AU$26.690m
- Shares outstanding: 342.18m
- Website: https://www.medlab.co
- Medlab Clinical Limited
- Building A
- Unit A5 – A6, Botany Quarter
- New South Wales
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/24 00:00|
|End of Day Share Price||2022/05/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.